CN118574642A - 作为治疗剂的肽微管蛋白抑制剂的肽缀合物 - Google Patents

作为治疗剂的肽微管蛋白抑制剂的肽缀合物 Download PDF

Info

Publication number
CN118574642A
CN118574642A CN202280089024.1A CN202280089024A CN118574642A CN 118574642 A CN118574642 A CN 118574642A CN 202280089024 A CN202280089024 A CN 202280089024A CN 118574642 A CN118574642 A CN 118574642A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280089024.1A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·约翰·马奎尔
约翰娜·玛丽·森格里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyberspace Corp 4
Original Assignee
Cyberspace Corp 4
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyberspace Corp 4 filed Critical Cyberspace Corp 4
Publication of CN118574642A publication Critical patent/CN118574642A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280089024.1A 2021-11-17 2022-11-16 作为治疗剂的肽微管蛋白抑制剂的肽缀合物 Pending CN118574642A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280409P 2021-11-17 2021-11-17
US63/280,409 2021-11-17
PCT/US2022/079973 WO2023091957A1 (en) 2021-11-17 2022-11-16 Peptide conjugates of peptidic tubulin inhibitors as therapeutics

Publications (1)

Publication Number Publication Date
CN118574642A true CN118574642A (zh) 2024-08-30

Family

ID=84799580

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280089024.1A Pending CN118574642A (zh) 2021-11-17 2022-11-16 作为治疗剂的肽微管蛋白抑制剂的肽缀合物

Country Status (14)

Country Link
US (1) US20230416331A1 (cg-RX-API-DMAC7.html)
EP (1) EP4433095A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024542212A (cg-RX-API-DMAC7.html)
KR (1) KR20240130157A (cg-RX-API-DMAC7.html)
CN (1) CN118574642A (cg-RX-API-DMAC7.html)
AU (1) AU2022390891A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243300A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001486A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024007413A2 (cg-RX-API-DMAC7.html)
IL (1) IL312884A (cg-RX-API-DMAC7.html)
MX (1) MX2024005938A (cg-RX-API-DMAC7.html)
PE (1) PE20242180A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330015A (cg-RX-API-DMAC7.html)
WO (1) WO2023091957A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006078816A2 (en) * 2005-01-18 2006-07-27 The Board Of Governors For Higher Education Selective delivery of molecules into cells or marking of cells in diseased tissue regions using environmentally senstive transmembrane peptide
EP2927227A4 (en) * 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
WO2018023098A1 (en) * 2016-07-29 2018-02-01 Memorial Sloan Kettering Cancer Center Radiolabeled ligands for targeted pet/spect imaging and methods of their use
MX2022000449A (es) * 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) * 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos

Also Published As

Publication number Publication date
EP4433095A1 (en) 2024-09-25
CL2024001486A1 (es) 2024-11-29
PE20242180A1 (es) 2024-11-07
AU2022390891A1 (en) 2024-06-06
CO2024007413A2 (es) 2024-11-18
IL312884A (en) 2024-07-01
CA3243300A1 (en) 2023-05-25
MX2024005938A (es) 2024-08-14
KR20240130157A (ko) 2024-08-28
TW202330015A (zh) 2023-08-01
JP2024542212A (ja) 2024-11-13
WO2023091957A1 (en) 2023-05-25
US20230416331A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
JP7673041B2 (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
TWI820077B (zh) 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
CN110305109B (zh) 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
JP2022541749A5 (cg-RX-API-DMAC7.html)
CN114302744B (zh) 作为治疗剂的微管靶向剂的肽缀合物
JP2019518747A (ja) 大環状インドール誘導体
US20230416331A1 (en) Peptide conjugates of peptidic tubulin inhibitors as therapeutics
CN118475579A (zh) 作为tead抑制剂的异双功能分子
EA051761B1 (ru) Пептидные конъюгаты агентов, нацеленных на микротрубочки, в качестве терапевтических средств
HK40128596A (zh) 吡啶并[4，3-d]嘧啶化合物
WO2022155172A1 (en) Peptide conjugates of therapeutics
HK40111548A (en) Selective bcl-xl protac compounds and methods of use
EA051826B1 (ru) Пептидные конъюгаты цитотоксинов в качестве терапевтических средств
HK40102634A (en) Compounds as immunomodulators of pd-l1 interactions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination